ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Georg Kääb contributed 79 entries already.
The new funding includes €2.5m grant and €10m equity investment and supports Belgian AmphiStar’s potential to reshape the surfactants market. This investment will accelerate scale-up and market entry of sustainable biosurfactants, which AmphiStar has already set up transatlantic in a recent partnership.
Basel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group.
The biotech company Actithera, with locations in Cambridge, USA, and Oslo, Norway, has successfully closed a major Series A round, raising US $75.5 million. Its isotope-agnostic platform — designed with a specific focus on the interaction between linker and target molecule — has attracted strong interest from a wide range of investors. However, the path to this achievement was not as straightforward as anticipated, CEO Andreas Goutopoulos told European Biotech News.
AFYREN’s first biorefinery, AFYREN NEOXY, has reached continuous production, marking a key step toward large-scale commercialisation of its bio-based acids. The plant will now ramp up output and fulfill long-term contracts across key sectors like nutrition, cosmetics, and life sciences. European Biotech News talked to CEO Nicolas Sordet about the long and winding road to sucess.
NLS Pharmaceutics secures US$2m equity funding and signs US$25m equity facility to support merger with Kadimastem (Israel) to combine expertise in aiming to become a leader in regenerative medicine in neurodegenerative disorders.
Zürich, 31 March 2025 –
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is an industry alliance to support research and development projects in AMR. Since its inception in 2016, CARB-X has supported 114 R&D projects across 14 countries, leading to 18 projects advancing into or completing clinical trials. EBM talked to CARB-X Executive Director Kevin Outterson.
UK focuses on digital health research: £600m (US$764m) for new data platform according to the five recommendations of the Sudlow report.
TIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.
French ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.
In February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential trade conflicts. While other nations are actively collaborating with industry to secure the future of their pharmaceutical sectors, Switzerland is abandoning the only federal initiative aimed at improving conditions for biomedical research. The organisation scienceindustries calls for a renewed effort by the government to develop a new master plan.